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Abstract
Background: Bone marrow multipotent mesenchymal stromal cells (MSCs) are a diverse subset of precursors that
contribute to the homeostasis of the hematopoietic niche. MSCs can be isolated and expanded in vitro and have
unique immunomodulatory and regenerative properties that make them attractive for the treatment of
autoimmune diseases, including type 1 diabetes (T1D). Whether autologous or allogeneic MSCs are more suitable
for therapeutic purposes has not yet been established. While autologous MSCs may present abnormal function,
allogeneic cells may be recognized and rejected by the host immune system. Thus, studies that investigate
biological characteristics of MSCs isolated from T1D patients are essential to guide future clinical applications.
Methods: Bone marrow-derived MSCs from recently diagnosed type 1 diabetes patients (T1D-MSCs) were
compared with those from healthy individuals (C-MSCs) for morphological and immunophenotypic characteristics
and for differentiation potential. Bioinformatics approaches allowed us to match absolute and differential gene
expression of several adhesion molecules, immune mediators, growth factors, and their receptors involved with
hematopoietic support and immunomodulatory properties of MSCs. Finally, the differentially expressed genes were
collated for functional pathway enrichment analysis.
Results: T1D-MSCs and C-MSCs were similar for morphology, immunophenotype, and differentiation potential. Our
absolute gene expression results supported previous literature reports, while also detecting new potential
molecules related to bone marrow-derived MSC functions. T1D-MSCs showed intrinsic abnormalities in mRNA
expression, including the immunomodulatory molecules VCAM-1, CXCL12, HGF, and CCL2. Pathway analyses
revealed activation of sympathetic nervous system and JAK STAT signaling in T1D-MSCs.
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Conclusions: Collectively, our results indicate that MSCs isolated from T1D patients present intrinsic transcriptional
alterations that may affect their therapeutic potential. However, the implications of these abnormalities in T1D
development as well as in the therapeutic efficacy of autologous MSCs require further investigation.
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Background
Multipotent mesenchymal stromal cells (MSCs) are a di-
verse subset of precursors found in the stromal fraction
of the bone marrow and other adult tissues, presenting
osteogenic, adipogenic, and chondrogenic differentiating
potentials [1–3]. Stromal cells are usually detected in
perivascular areas and present immunomodulatory prop-
erties [1, 4]. They have therefore been explored as tools
to modulate inflammatory response, induce peripheral
tolerance, and promote tissue repair [5]. In addition,
murine bone marrow MSCs are physically close to most
hematopoietic stem cells (HSCs) and express high levels
of genes related to HSC maintenance and retention,
which makes them important contributors for matur-
ation of the hematopoietic compartment [6–9].
MSCs can be expanded in vitro and have unique im-
munomodulatory and regenerative properties, which
render them attractive for treatment of autoimmune and
inflammatory disorders [10]. Initial studies revealed
that bone marrow MSCs inhibited T-cell proliferation
in vitro and were immunosuppressive in a model of
skin allograft rejection [11–13]. In addition, bone
marrow MSCs were shown to inhibit dendritic cell
differentiation and B-cell proliferation, impair the
cytolytic potential of natural killer cells, and increase T
regulatory cell (Treg) differentiation and function [10, 14].
The therapeutic effects of MSCs are partially due to their
ability to produce and secrete a vast array of soluble
mediators and other molecules with immunomodulatory
properties, such as hepatocyte growth factor (HGF),
indoleamine 2,3-dioxygenase (IDO), cyclooxygenase-2
(COX2), IL-10, prostaglandin E2, nitric oxide, and
transforming growth factor beta 1 (TGFβ-1) [14].
In the last decade, many studies have demonstrated
the therapeutic potential of MSC transplantation in ex-
perimental models of autoimmune diseases, including
type 1 diabetes (T1D) [15–18]. In 2006, Lee et al. [19]
showed that human MSCs were able to migrate and
promote pancreatic repair in nonobese diabetic/severe
combined immunodeficiency (NOD/SCID) mice. Later,
several other studies in experimental models of T1D
have demonstrated that MSC transplantation delays the
onset of disease or even reverses hyperglycemia [18–21].
Further investigations have shown modulation of the in-
flammatory response and expansion of Tregs, in conse-
quence decreasing pancreatic infiltrates and improving
endogenous insulin production [20–23]. Transdifferen-
tiation is not considered a major therapeutic mechanism
of MSCs in T1D. Instead, cytokine and soluble factor
release may account for immunosuppressive, anti-
inflammatory, and regenerative properties that abrogate
the autoimmune response and stimulate the survival and
proliferation of resident/progenitor pancreatic cells
through paracrine pathways [24].
In-vitro expanded MSCs are able to escape the im-
mune system when administered intravenously, and may
be useful tools in the allogeneic transplantation setting
[25]. Under resting conditions, MSCs express low levels
of major histocompatibility complex (MHC) class I, and
do not express MHC class II or co-stimulatory mole-
cules, such as CD80, CD86, CD40, or CD40L [26, 27].
The modulatory activity of MSCs depends on a process
of “licensing” promoted by proinflammatory cytokines,
especially tumor necrosis factor (TNF) and interferon
gamma (IFN-γ) [28–34]. In a murine model, MSCs
treated with high IFN-γ levels before infusion became
immediately activated and were able to suppress graft
versus host disease (GvHD) more efficiently than a
fivefold-greater number of MSCs that had not been pre-
treated [35]. Conversely, under low IFN-γ levels MSCs
upregulate the expression of MHC class II, behave as
antigen-presenting cells, and, in consequence, may be
recognized by alloreactive cells after transplantation
[36–40]. Accordingly, whether allogeneic MSCs persist
in the tissues of immunocompetent hosts after trans-
plantation still remains under debate [41].
In the field of human autoimmune diseases, results are
frequently divergent and lack consistency. In patients
with Crohn’s disease (CD) [42], rheumatoid arthritis
(RA) [43], systemic sclerosis (SSc) [44], and multiple
sclerosis (MS) [45], MSCs were shown similar to those
from healthy controls. In other studies, however, abnor-
malities were described in MSCs isolated from patients
with SSc [46, 47], systemic lupus erythematosus (SLE)
[48, 49], MS [50], and psoriasis [51–54]. While the clin-
ical relevance of such findings has not yet been estab-
lished, currently there is weak support for either
autologous or allogeneic MSC-based therapies.
In-vivo studies are also somewhat contradictory. In
T1D patients, a small clinical trial showed modest but
significant preservation of C-peptide levels after trans-
plantation with autologous MSCs [55]. Accordingly, in
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animal models, murine MSCs from both healthy and
diabetic animals were therapeutically effective [56, 57].
On the other hand, when murine bone marrow-derived
MSCs were used to treat prediabetic NOD mice, onset
of disease was delayed by MSCs isolated from BALB/c,
but not by autologous MSCs [55]. These data indicate
that available evidence is still not strong enough to sup-
port a recommendation and that more studies should be
performed in order to fully establish advantages and
weaknesses of autologous or allogeneic MSCs.
Further studies to investigate the genetic and bio-
logical profiles of MSCs isolated from patients with
autoimmune diseases are still warranted. To the best of
our knowledge, it remains unknown whether MSCs iso-
lated from newly diagnosed T1D patients have a similar
molecular profile compared with their healthy coun-
terparts. For this purpose, we characterized the global
gene expression of bone marrow MSCs isolated from
healthy individuals (controls, C-MSCs) and newly di-
agnosed T1D patients (T1D-MSCs). Herein, we de-
scribe the absolute and differential gene expression of
several molecules involved with immunomodulation and
hematopoietic support in C-MSCs and T1D-MSCs.
Methods
Patients and controls
Twenty-one T1D patients of median age 16 (range 13–
31) years, 71 % (n = 15) male, were enrolled in this study,
having been diagnosed with T1D within the previous
6 weeks. All patients had positive serum levels of anti-
glutamic acid decarboxylase (anti-GAD) antibodies, and
did not report any previous episodes of diabetic ketoaci-
dosis (Additional file 1: Table S1). The control group in-
cluded 10 healthy subjects, 50 % male (n = 5), with
median age 34 (range 19–48) years, who had already
been enrolled as bone marrow donors for allogeneic
transplantation, and who voluntarily agreed to donate an
additional 5 ml of bone marrow aspirate for research.
All procedures were approved by the Institutional
Review Board (Research Ethical Committee of Clinical
Hospital of Ribeirao Preto Medical School, CEP-HCRP-
USP #10095/02) and written informed consent was
obtained from all individuals before bone marrow aspir-
ation. Bone marrow samples were obtained from T1D
patients and healthy donors through needle aspiration of
the iliac crest.
Isolation and culture of bone marrow MSCs
Bone marrow aspirates were collected in the presence of
EDTA, and mononuclear cells were separated by Ficoll-
Hypaque (Amersham-Pharmacia, Uppsala, Sweden) gra-
dient density separation. Subsequently, the mononuclear
cell layer was harvested and washed twice in PBS. Cells
were centrifuged and resuspended in alpha-Minimum
Essential Medium (α-MEM; Gibco, Life Technologies,
Grand Island, NY, USA) medium supplemented with 15 %
fetal bovine serum (FBS; Thermo Scientific, Rockford, IL,
USA), 100 μg/ml penicillin, 100 μg/ml streptomycin, and
2 mML-glutamine (all from Gibco, Life Technologies).
The cells were then seeded in 75 cm2 flasks and incubated
at 37 °C in a humidified atmosphere containing 5 % CO2
(passage 0). After 24 h, nonadherent cells were removed
by replacing the medium, and fresh medium was added.
The culture was examined daily by phase-contrast mi-
croscopy and every 3 days the medium was partially
changed to remove nonadherent cells and cell debris.
When the cells reached at least 70–80 % confluence,
they were detached using trypsin–EDTA 0.05 % (Gibco,
Life Technologies) and passaged at a split ratio of 1:2 until
the third or fourth passage.
MSC morphology and immunophenotypic profiling
After expansion in culture until the third or fourth
passage, C-MSCs and T1D-MSCs were assessed for
morphology by inverted (Axiovert 40 CFL; Carl Zeiss,
Goetingen, Germany) and light (TS100; Nikon, China)
microscopy. C-MSCs and T1D-MSCs were then incu-
bated with monoclonal antibodies against CD45, CD14,
CD44, CD29, CD51/61, CD13, CD54, HLA-CLASS I
(HLA-A/B/C), HLA-CLASS II (HLA-DRB1), CD90,
KDR, CD34, CD49e, CD105, CD73, or STRO-1 (Becton-
Dickinson (BD), San Jose, CA, USA) for 30 min in the
dark. Immunophenotypic analysis was performed using
FACSCalibur (BD) equipment and 20,000 cells were ac-
quired and analyzed by FlowJo 10 software.
Differentiation into mesoderm lineages
In-vitro adipogenic differentiation of C-MSCs and T1D-
MSCs was induced using α-MEM medium supplemented
with 15 % FBS, 100 mM dexamethasone (Prodome,
Campinas, SP, Brazil), 10 μg/ml insulin (Sigma-Aldrich,
Saint Louis, MO, USA), and 100 μM indomethacin
(Sigma-Aldrich). MSCs cultured with α-MEM medium
supplemented with 15 % FBS served as the negative con-
trol. Culture medium was changed every 3 days and cells
were maintained in culture for 21 days. MSCs were then
fixed with ethanol (70 %) and stained with Sudan II-
Scarlate and Harris hematoxylin. The presence of
lipid vacuoles in the MSCs was observed through
light microscopy.
Osteoblastic differentiation was initiated by seeding
MSCs in the presence of osteogenic differentiation
medium composed of MSC growth medium; that is,
α-MEM supplemented with 7.5 % FBS plus 1 M
glycerol-2-phosphate (Sigma-Aldrich), 20 mM L-ascor-
bic acid (Sigma-Aldrich), and 0.1 mM dexamethasone
(Sigma-Aldrich). The culture medium was replaced
every 3 days during a period of 21 days. During the
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same period, control cells were kept in standard α-MEM
with 7.5 % FBS (HyClone; Thermo Fisher Scientific
Inc., USA).
All cells were fixed and stained by the von Kossa
method, which indicates calcium deposition, subsequently
analyzed with an Axioscope 2.0 Zeiss microscope
equipped with an AxioCam HR camera (Carl Zeiss).
For chondrogenic induction, 106 cell pellets were cul-
tured for 3 weeks under chondrogenic medium containing
10 ng/ml of TGF-β3 (PeproTech, USA), 100 μM sodium
pyruvate (Gibco, Carlsbad, CA, USA), 0.1 μM dexametha-
sone (Decadron, Brazil), 50 μM ascorbic acid, 0.5× ITS A
(insulin–transferrin–selenium-sodium pyruvate A; Gibco),
and 0.2 % human albumin (Aventis Behring, Australia)
PeproTech in DMEM (Gibco). Cell pellets were harvested
at 3 weeks post induction, fixed overnight with 4 % PFA,
and sections were prepared for immunohistochemistry.
For staining, sections were incubated with anti-type II col-
lagen rabbit antibody (Novocastra™, Newcastle, UK), and
subsequently stained with hematoxylin and eosin and ana-
lyzed with an Axioscope 2.0 Zeiss microscope equipped
with an AxioCam HR camera (Carl Zeiss).
Microarray analysis
Total RNA was isolated from random T1D-MSCs (n = 11)
and C-MSCs (n = 10) by the Trizol method (Invitrogen,
USA) and purified by RNeasy commercial kit (QIAGEN,
USA) according to the manufacturers’ recommendations.
RNA integrity was evaluated by microfluidic electrophor-
esis using Agilent 6000 RNA Nano chips and an Agilent
2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA,
USA). Only RNA samples that were free of proteins and
phenol and that featured an RNA Integrity Number
(RIN) ≥ 9.0 were used. Random RNA samples of T1D-
MSCs and C-MSCs were selected (n = 4 for each group)
and the global gene expression was analyzed by the
One-color Microarray-Based Gene Expression Analysis
Protocol system (Agilent Technologies) on glass slides
with four microarrays of 44,000 probes each (4 × 44 k).
The preprocess and statistical microarray analyses were
performed using algorithms available in the R plat-
form (R Foundation, Vienna, Austria) through the
Linear Models for Microarray Data (LIMMA) package
[56]. Heatmaps were generated by the HeatMapViewer
module of GenePattern 2.0 software [57]. Genes with
p < 0.05 and fold change (FC) > 2.0 were considered
differentially expressed. Microarray data were deposited in
the public database ArrayExpress (http://www.ebi.ac.uk/
arrayexpress [ArrayExpress:E-MTAB-2976]).
Absolute and differential expression of predefined gene
categories
Encoding genes for collagens, integrins, and laminins, as
well as for cytokines, growth factors, and chemokines,
and their respective receptors, were classified according
to the binary relationships of biological entities (BRITE)
category available in the Kyoto Encyclopedia of Genes
and Genomes (KEGG) database [58]. Different categor-
ies were represented by heatmaps generated by the
HeatMapViewer module of the GenePattern 2.0 software
[57]. Genes with multiple probes were represented by
the median value. For absolute gene expression repre-
sentation, genes in each category were sorted in ascend-
ing order, according to average value expression of the
control group. Highly expressed genes had absolute gene
expression value (EV) > 120. Only genes with p < 0.05
and FC > 2.0 were included in the heatmaps for differen-
tial gene expression.
Functional enrichment analysis
The functional enrichment analysis was performed using
DAVID software (Database for Annotation, Visualization
and Integrated Discovery; National Cancer Institute at
Frederick, Frederick, MD, USA) [59, 60]. The differ-
entially expressed official gene symbols (upregulated
and downregulated) were imported to the program
and the Functional Annotation Chart module was
used. In this module, we performed a standard ontol-
ogy (GO FAT) available for all categories of the Gene
Ontology database (biological process, molecular function,
and cellular component), as well as analysis of the
KEGG pathways database. Categories and pathways
with p > 0.05 were considered statistically significant
(Benjamini correction).
Gene set enrichment analysis
Gene set enrichment analysis (GSEA) was performed
using the GSEA 2.07 software (Broad Institute from
Massachusetts Institute of Technology, MIT, Cambridge,
MA, USA). The differentially expressed probes (p < 0.05)
were imported to the program, and gene ontology and
KEGG pathway analyses were performed with 1000 per-
mutations (gene set type) for p-value calculation. Default
parameters were used, except for “collapsing mode for
probe sets = > 1 gene”, in which the median value was
used. Categories with nominal p < 0.05 and false dis-
covery rate (FDR) < 0.25 were considered statistically
significant.
Functional pathway analysis
To assess biological relationships among genes, the
gene list with p < 0.05 and FC > 2.0 were ascertained
using the Ingenuity Pathway Analysis (IPA) software
(Ingenuity System, Redwood City, CA, USA; http://
www.ingenuity.com), which assigns a p value to each
network, according to the degree of overrepresenta-
tion of input genes as compared with the Ingenuity
Pathways Knowledge database.
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Real-time PCR
cDNA was synthesized from different RNA samples used
for microarrays (T1D-MSCs, n = 7 and C-MSCs, n = 6)
using 200 ng of total RNA (High-Capacity cDNA Reverse
Transcription Kit; Life Technologies, USA). For microarray
validation, real-time PCR was performed with the Taqman
Gene Expression Assay (Applied Biosystems, USA) accord-
ing to the manufacturer’s protocol. Target gene expression
was calculated using the comparative method for relative
quantification after normalization to GAPDH gene expres-
sion: GAPDH, Hs02758991_g1; CXCL12, Hs03676656_mH;
and VCAM1, Hs01003372_m1.
In-vitro migration assay
In-vitro migration was assayed by transwell chamber
(BD, Franklin Lakes, NJ, USA) with 8 μm porosity poly-
ethylene terephthalate (PET) membrane. C-MSCs (n = 5)
and T1D-MSCs (n = 5) were seeded in the upper layers
of membranes with 100 μl of α-MEM medium without
FBS. One chamber was inserted into each well of a
24-well plate filled with 600 μl of α-MEM supple-
mented with 50 % FBS. MSCs were incubated for 6 h
at 37 °C. Cells that passed through the membrane
pores to the underside were counterstained by Giemsa
(Sigma-Aldrich). Nonmigrated cells were scraped off the
upper surface of the membrane with a cotton swab. For
each membrane, the number of migrated MSCs was
counted in seven different fields using light microscopy.
Results
T1D-MSCs present typical morphology, immunophenotype,
and mesodermic lineage differentiation
T1D-MSCs or C-MSCs were morphologically and
immunophenotypically characterized in vitro. We did
not observe differences between C-MSCs and T1D-
MSCs concerning proliferative capacity or doubling time
(data not shown). In general, MSCs isolated from both
groups achieved 70–80 % confluence every 7 days. MSCs
appeared as a typical monolayer of spindle-shaped
fibroblast-like cells and demonstrated ability to adhere
to plastic during in-vitro expansion. At the third passage,
T1D-MSCs were morphologically similar to C-MSCs
(Fig. 1a). No significant difference between T1D-MSCs and
C-MSCs was observed in the expression of typical MSC
markers. Both MSC populations were positive for CD90,
CD13, CD29, CD105, CD49e, CD73, CD44, HLA-ABC,
CD166, CD54, CD106, and STRO-1, and were negative for
the hematopoietic/endothelial markers CD51/61, CD45,
CD34, CD14, HLA-DR, and KDR (Fig. 1b, Additional file 2:
Table S2). Furthermore, cultured T1D-MSCs and C-MSCs,
under specific stimuli, were able to differentiate towards
adipogenic, osteogenic, and chondrogenic lineages (Fig. 1c).
Fig. 1 In-vitro expanded MSCs from type 1 diabetes patients (T1D-MSCs) show typical spindle-shaped morphology, mesodermic differentiation
potential, and immunophenotypical profile. a Morphological characterization of T1D-MSCs at 40× (left) and 100× (right) magnification. b Representative
histograms of positive and negative MSC surface markers. c Adipogenic, osteogenic, and chondrogenic differentiation of T1D-MSCs at 40× (left) and
100× (right) magnification. MSC multipotent mesenchymal stromal cell
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Transcriptional profile of T1D-MSCs is distinct from their
healthy counterparts
To investigate whether T1D-MSCs present transcrip-
tome abnormalities and to better understand molecular
pathways that may regulate T1D-MSC biology, we per-
formed a global gene expression analysis by microarray.
Unsupervised clustering analysis showed distinctive
gene expression signatures comparing T1D-MSCs to
C-MSCs (Additional file 3: Figure S1) and we ob-
served differential expression of 2978 probes between
the groups (FC > 2, p < 0.05). Most of these probes
were found upregulated in T1D-MSCs, when com-
pared with C-MSCs (1926 upregulated and 1052
downregulated probes) (Fig. 2).
Aside from their role as structural elements, MSCs
serve as resident sentinels that, upon activation, ex-
press surface molecules and produce soluble factors,
coordinating tissue regeneration and inflammatory re-
sponses [4, 61]. In order to characterize the gene
expression of several adhesion molecules, immune
mediators, growth factors, and their receptors in bone
marrow-derived MSCs from T1D patients and healthy
controls, we first determined which mRNAs were
more intensively expressed, using absolute gene ex-
pression analysis. Then, we specifically investigated
which of these molecules were differentially expressed
between T1D-MSCs and C-MSCs.
VCAM-1 and other adhesion-related molecules are
differentially regulated in T1D-MSCs
Cultured MSCs from both groups (T1D-MSCs and C-
MSCs) presented increased absolute mRNA expression of
collagens, integrins, laminins, and other molecules related
to extracellular matrix (ECM) maintenance, cell–cell adhe-
sion, and cell–ECM interaction (EV > 120). Genes encoding
type I, IV, V, VI, and VIII collagens were overexpressed
(Fig. 3a), as well as those for CD29 (ITGB1), CD51
(ITGAV), and CD49a (ITGA1) (Fig. 3b). A similar increase
was observed for codification of the three types of laminin
chains, especially the β chain (Fig. 3c), and for other
adhesion-related genes (absolute expression), such as
VCAM1,THY1, and CD44 (Additional file 4: Figure S2).
Bioinformatics analysis was used to identify adhesion-
related genes that were differentially expressed between
T1D-MSCs and C-MSCs (FC > 2.0, p < 0.05). VCAM1
was found downregulated in T1D-MSCs, and differences
were also detected for expression of SEMA4A, ITGA7,
ITGB1, and LAMA3 (Fig. 4a). Microarray analysis was
validated by quantitative real-time PCR, confirming that
VCAM1 was downregulated in T1D-MSCs (Fig. 4b).
CXCL12, CCL2, and other chemotaxis-related molecules
are differentially regulated in T1D-MSCs
MSCs are able to migrate to sites of inflammation and
to regulate the traffic of different hematopoietic cells.
Fig. 2 Distinct global gene expression in T1D-MSCs and C-MSCs. A total of 2149 genes were differentially expressed between T1D-MSCs (n = 4)
and C-MSCs (n = 4). T1D-MSCs showed 1515 upregulated genes and 634 downregulated genes (FC > 2, p < 0.01, Student t test, Benjamini Hochberg
correction). a Volcano plot of differentially expressed probes between T1D-MSCs and C-MSCs. Each plot represents one probe. Upregulated probes in
T1D-MSCs are shown in red and downregulated probes in green. b Supervised clustering of differentially selected probes. T1D type 1 diabetes
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Chemokines and their receptors are key molecules for
such activities [62]. Thus, we determined the absolute
gene expression of chemokines and chemotaxis-related
molecules in T1D-MSCs and C-MSCs. Our analyses de-
tected increased absolute expression of genes encoding
CXCL12, CCL24, chemokine-like factor (CKLF), CXCL5,
and, especially, CCL2 (MCP-1) in MSCs from both
groups (Fig. 5a). Among the chemokine receptors,
CXCR3 was mostly expressed (Fig. 5b). Additionally,
CXCL12, CCL2, CCL24, and CXCL5 were downregulated
in T1D-MSCs compared with C-MSCs (Fig. 5c). Down-
regulation of CXCL12 was confirmed by real-time PCR
(Fig. 5d). Furthermore, despite having low absolute ex-
pression (EV < 120), genes encoding the chemokines
CCL13, CCL15, CXCL16, and CCL3L3 and receptors
CCR3, CXCR5, and Duffy antigen/chemokine receptor
(DARC) were upregulated in T1D-MSCs compared with
their healthy counterparts. Conversely, CCL7 was down-
regulated (Fig. 5c).
Differential expression of genes encoding cytokines,
growth factors, cytokine/growth factor receptors, and
matrix metallopeptidases
Cytokines and matrix metallopeptidase (MMP)-related
molecules play a fundamental role in MSC-mediated im-
mune regulation, in tissue regeneration, and also in
MSC migration [62]. These functions are also associated
with the expression of receptors on the surface of the
MSCs, including the “licensing” receptors for IFN-γ and
TNF-α [29]. In our analysis, both C-MSCs and T1D-
MSCs presented increased absolute expression of genes
encoding cytokines (IL-6, TGF-β1), growth factors
(platelet-derived growth factor (PDGF), vascular endo-
thelial growth factor (VEGF), fibroblastic growth factor
Fig. 3 MSCs show high absolute gene expression of adhesion-related molecules. Absolute expression of genes encoding a collagens, b integrins,
and c laminins in MSCs from healthy donors (Controls) and T1D patients (Diabetic). Genes with multiple probes were represented by the median
value. The absolute gene EV was log2-transformed, and blue indicates high expression
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(FGF), HGF) and MMP-related molecules such as
MMP-2, MMP-9, and MT1-MMP (Fig. 6).
Further analysis revealed 24 genes encoding cytokines
or growth factors, 17 receptors for these molecules, and
nine MMP-related proteins differentially expressed be-
tween T1D-MSCs and C-MSCs. Of these, FGF3 and
HGF (Fig. 7a), as well as EGFR and FGFR1 (Fig. 7b),
were downregulated in T1D-MSCs, while MT1-MMP
(MMP14) and MMP2 were upregulated in T1D-MSCs
(Fig. 7c), when compared with their healthy counter-
parts. Both MMP14 and MMP2 are related to MSC mi-
gratory capacity. Indeed, we observed higher migratory
capacity in MSCs from T1D patients than in those from
healthy controls (Additional file 5: Figure S3).
Hyperactivation of sympathetic nervous system signaling
in T1D-MSCs
Signature sequence probe lists were analyzed by collat-
ing genes into functional pathways in the KEGG data-
base and ranking those pathways on the basis of
statistical overrepresentation with the DAVID bioinfor-
matics database and GSEA. DAVID analysis of the up-
regulated genes revealed enrichment of the neuroactive
ligand–receptor interaction canonical pathway in T1D-
MSCs (Additional file 6: Table S3). The same pathway
was also significantly and positively correlated with
T1D-MSCs in the GSEA analysis (Fig. 8a,b). The neuro-
active ligand–receptor interaction pathway signaling is
triggered by activation of G protein-coupled receptors
that indirectly regulate opening and closing of ion chan-
nels after neurotransmitter binding [63]. When examin-
ing genes contained in this pathway, we found important
upregulation of the β3-adrenergic receptor-encoding
gene (ADRB3), suggesting activation of the adrenergic
system in T1D-MSCs (Fig. 8c).
To further investigate the hyperactivation of the ad-
renergic system, we then analyzed the expression of
downstream genes involved in the β3-adrenergic signal-
ing. For this purpose, we imported the data of differen-
tially expressed probes into the IPA software and, as
expected, most of the G protein-coupled receptor ca-
nonical pathway genes were upregulated (Fig. 9).
Discussion
In the bone marrow, MSCs are in close contact with
HSCs and express several factors responsible for the
Fig. 4 VCAM-1 and other adhesion-related molecules are differentially regulated in T1D-MSCs. a Heatmap of adhesion-related genes differentially
expressed between MSCs from healthy donors (Controls, n = 4) and T1D patients (Diabetic, n = 4) (FC > 2, p < 0.05, Student t test, Benjamini Hochberg
correction). Upregulated genes are shown in red and downregulated genes in green. b Relative expression of VCAM1 by real-time PCR (Diabetic, n = 7;
Control, n = 6). Mann-Whitney U test, p = 0.0041. VCAM-1 vascular cell adhesion protein 1
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innate and adaptive immune cell maturation and sup-
port [64]. Additionally, in-vitro expanded MSCs isolated
from bone marrow samples are able to modulate the im-
mune system and have been investigated as treatment
for several immune-mediated disorders [5]. However, it
remains a matter of debate whether autologous or allo-
geneic MSCs are more suitable for therapeutic purposes
in this context. On one hand, functionally compromised
autologous MSCs may be therapeutically ineffective. On
the other, allogeneic MSCs may be rejected by the host
competent immune system [41].
Here, we demonstrate that in-vitro expanded T1D-
MSCs present similar morphology, immunophenotype,
and multipotential differentiation when compared with
MSCs derived from healthy controls. However, our tran-
scriptome analysis revealed more than 2000 probes dif-
ferentially expressed between T1D-MSCs and C-MSCs.
Cellular function is a consequence of the interaction
between DNA sequence, epigenetic status, mRNA and
miRNA expression, and protein content, among other
components. Although gene expression analysis offers
limited information and some reports have shown no-
toriously poor correlation between mRNA and protein
expression levels, it has been described that differentially
expressed mRNAs correlate significantly better with
their protein product than nondifferentially expressed
mRNAs [65]. Thus, although in our study an absence of
validation by other methods or functional experiments is
a limitation, we believe that global transcriptomic ana-
lysis is a strong enough method to identify markers, in-
cluding molecular pathways, surface receptors, and
secreted factors, for further detailed studies.
Studies addressing potential abnormalities in MSCs
derived from patients with autoimmune or inflammatory
disorders are scarce and somewhat contradictory. While
some authors report phenotypic, proliferative, and gen-
etic abnormalities in cells derived from diseased patients,
others describe them as nondifferent from their healthy
Fig. 5 CXCL12, CCL2, and other migration-related molecules are differentially regulated in T1D-MSCs. Absolute gene expression of genes
encoding a chemokines and b chemokine receptors. Genes with multiple probes were represented by the median value. The absolute
gene expression value (EV) was log2-transformed, and blue indicates high expression. c Heatmap of the migration-related genes differentially expressed
between MSCs from healthy donors (Control, n = 4) and T1D patients (Diabetic, n = 4) (FC > 2, p < 0.05, Student t test, Benjamini Hochberg correction).
Upregulated genes are shown in red and downregulated genes in green. d Relative expression of CXCL12 by real-time PCR (Diabetic, n = 7; Control,
n = 10). Mann-Whitney U test, p = 0.0054
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counterparts [45–54]. Expressions of the TGF-β receptor
gene and protein were found defective in MSCs from
SSc patients [46], and IL-6 and IL-7 mRNA were down-
regulated in MSCs from SLE patients [48]. Mesenchymal
cells derived from the skin of psoriasis patients produced
more angiogenic and proinflammatory mediators and
showed reduced antioxidant capacity when compared
with those isolated from control specimens [51]. Micro-
array and genome-wide promoter methylation analyses
revealed that skin-derived MSCs from psoriasis patients
presented aberrant proliferative activity and increased
apoptosis rates, markedly different from healthy control
MSCs [52–54]. Recently, our group demonstrated gen-
etic and functional alterations in MSCs isolated from
MS patients (MS-MSCs) [50]. MS-MSCs in culture pre-
sented a senescent phenotype and reduced antiprolifera-
tive potential. In addition, microarray analysis showed
618 differentially expressed genes, including downregu-
lation of TGFB1 and HGF. Together, these results indi-
cate that alterations may be disease specific and that
abnormalities can involve different aspects of MSC func-
tion or morphology.
To provide better understanding of the potential mole-
cules expressed by MSCs and to evaluate which of these
were differentially expressed between T1D-MSCs and C-
MSCs, we matched the absolute and differential gene
expression of several adhesion molecules, immune medi-
ators, and growth factors and their receptors. Such
analyses allowed us to identify the most relevant
differentially expressed molecules, considering the biol-
ogy of MSCs. Our gene expression data corroborated
previous reports, while revealing new molecules poten-
tially related to bone marrow MSC function. As ex-
pected, MSCs from both groups of patients (T1D-MSCs
and C-MSCs) presented high absolute expression of sev-
eral well-described adhesion molecules, such as collagen
VI [66], laminin-5 [67], integrins [68], fibronectin-1, and
intercellular adhesion molecule-1 (ICAM-1) [69]. Add-
itionally, in accordance with the literature, other import-
ant molecules were also found highly expressed in our
analysis, such as VEGF [70–73], PDGF [73], FGF-2
[74, 75], HGF [70, 72, 76, 77], and the licensing re-
ceptors for IFN-γ and TNF [29, 31, 40, 78–80].
Focusing on the differential gene expression of immu-
noregulatory molecules between T1D-MSCs and C-
MSCs, we found that vascular cell adhesion molecule-1
(VCAM-1) was downregulated in MSCs from T1D
patients. Previous reports have shown that under
inflammatory stimuli, MSCs produce large amounts of
chemokines and upregulate VCAM-1 expression, which
interacts with very late antigen-4 (VLA-4), rendering
MSCs more adhesive to activated T cells [29]. This close
proximity is pivotal for the immunosuppressive effect of
MSCs [31]. Our results therefore suggest that this cell
contact-dependent suppressive function of MSCs may
be impaired in T1D patients.
We observed downmodulation of the HGF gene in
T1D-MSCs. Indeed, HGF is also less expressed by bone
Fig. 6 MSC absolute gene expression of cytokines, growth factors, receptors, and MMPs corroborates previous literature reports. Absolute gene
expression of genes encoding a cytokines and growth factors, b cytokine/growth factor receptors, and c metalloprotease-related molecules.
Genes with multiple probes were represented by the median value. The absolute gene expression value (EV) was log2-transformed, and blue
indicates high expression. T1D-MSCs (Diabetic; n = 4) and C-MSCs (Control; n = 4). MMP matrix metallopeptidase. IL interleukin, PDGF platelet-
derived growth factor, TGFβ transforming growth factor beta, TNF tumor necrosis factor, VEGF vascular endothelial growth factor
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marrow MSCs isolated from MS patients [50]. This
pleiotropic cytokine that binds the tyrosine kinase trans-
membrane receptor c-Met [81] is associated with angio-
genesis and cell survival [82, 83]. Injections of HGF
stimulate kidney and liver regeneration, and prevent the
onset of renal failure [84]. In experimental autoimmune
encephalomyelitis (EAE) models, HGF secreted by MSCs
promotes neural cell development and remyelination
[85]. Interestingly, HGF is also suggested to be a cyto-
protective factor for pancreatic β cells [21, 86, 87], and
streptozotocin (STZ)-induced insulitis is observed to a
higher degree in c-Met null mice than in wild-type litter-
mates [88]. The HGF/c-Met signaling pathway is consid-
ered important for β-cell protection and proliferation in
conditions of metabolic stress [89]. Thus, the observed
downregulation of HGF in MSCs from T1D patients
may indicate a decreased potential for pancreatic regen-
eration. Additionally, genes encoding the receptors epi-
dermal growth factor receptor (EGFR) and fibroblastic
growth factor receptor (FGFR) were also found down-
regulated in our T1D-MSCs. These receptors regulate
stemness, and inhibit senescence, and are essential for
cell growth, tissue repair, and homeostasis [90, 91].
Interestingly, EGFR signaling increases secretion of HGF
[90, 92, 93]. We believe that downmodulation of HGF in
T1D-MSCs may be a result of decreased EGFR
signaling.
Moreover, membrane type 1-matrix metalloproteinase
(MT1-MMP) and MMP2, whose encoding genes were
found upregulated in T1D-MSCs, are essential for the
invasive capacity of MSCs [94–102]. Interestingly, T1D-
MSCs present higher migration capacity than C-MSCs.
On the other hand, we detected downregulation of genes
encoding CCL2, which is an important regulator of bone
marrow monocyte emigration [103]. In EAE mice, the
metalloproteinase-mediated paracrine proteolysis of
CCL2 is key for the efficacy of murine MSC-based ther-
apy. Indeed, MSCs that are CCL2-deficient have im-
paired ability to suppress IL-17 production by activated
T cells and, in consequence, lose their protective effect
[104, 105]. It has been described that MSCs cultured
alone without cytokines produce minimal amounts of
chemokines, and that unprimed MSCs cannot attract T
cells [29]. Of note, our study analyzed MSCs after
Fig. 7 T1D-MSCs show distinct expression of genes encoding cytokines, growth factors, cytokine/growth factor receptors, and MMPs. Heatmap of
a cytokines and growth factors, b cytokine/growth factor receptors, and c MMP genes differentially expressed between T1D-MSCs and C-MSCs
(FC > 2, p < 0.05, Student t test, Benjamini Hochberg correction). Upregulated genes are shown in red and downregulated genes in green. T1D-
MSCs (Diabetic; n = 4) and C-MSCs (Control; n = 4). MMP matrix metallopeptidase
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culturing and we were not able to determine whether
these changes are related to culturing conditions beyond
their exposure to the altered diabetic bone marrow
milieu. How these gene expression alterations may affect
therapeutic efficacy of bone marrow MSCs of T1D pa-
tients remains unknown and further functional experi-
ments are still warranted.
Finally, to identify previously unknown immunologic-
ally relevant pathways associated with T1D-MSCs, we
uploaded the differentially expressed genes into DAVID
and GSEA bioinformatics databases. We detected prefer-
ential enrichment of canonical pathways related to
sympathetic hyperactivity and also upregulation of the
β3-adrenergic receptor gene ADRB3 in T1D-MSCs. In
the bone marrow, nerve fibers that are physically associ-
ated with MSCs contribute to the circadian oscillation of
HSC mobilization [6, 106, 107]. This event is mainly
controlled by sympathetic nervous system (SNS) sig-
naling through the expression of β3-adrenergic recep-
tors in bone marrow MSCs, and negatively regulates
important HSC maintenance factors, such as CXCL12
and VCAM-1 [6]. T1D patients present bone marrow
abnormalities, and are poor HSC mobilizers [108–111].
Indeed, STZ-induced diabetes mice present aberrant SNS
Fig. 8 Pathway analysis suggesting hyperactivation of sympathetic nervous system signaling in T1D-MSCs. GSEA analysis of differentially expressed
probes between T1D-MSCs and C-MSCs. a Enrichment analysis in KEGG pathways positively correlated with T1D-MSCs relative to C-MSCs; blue
indicates KEGG pathways with higher normalized enrichment score (NES). Only data sets with p < 0.05 and FDR > 0.25 are shown. b Enrichment
plot of the neuroactive ligand–receptor interaction KEGG pathway: green curve indicates the enrichment score (ES); black vertical dashed lines
specify the maximum enrichment score. c Heatmap showing expression of genes in the leading edge subsets. The ADRB3 gene is shown in bold.
Diabetic T1D-MSCs, Control C-MSCs
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signaling in the bone marrow, with impaired expression of
CXCL12 [109]. In line with these literature reports, our
differential microarray analysis showed downregulation of
both HSC maintenance molecules, CXCL12 and VCAM1,
in T1D-MSCs.
Conclusions
Collectively, our findings demonstrate that bone marrow
MSCs isolated from newly-diagnosed T1D patients have
similar morphology, immunophenotypic profiling, and
multipotential differentiation when compared with
MSCs from healthy subjects. However, microarray ana-
lysis revealed several intrinsic abnormalities in their
mRNA expression. MSCs from T1D patients presented
enriched canonical pathways related to sympathetic in-
nervation and consequent SNS signaling hyperactivity,
with increase of β3-adrenergic receptor gene expression.
To our knowledge, this is the first report of transcrip-
tional profiling of MSCs isolated from the bone marrow
of T1D patients. The implications of these intrinsic gen-
etic alterations in T1D development as well as in the
therapeutic efficacy of autologous MSC transplantation
require further investigation.
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